Faculty from The Ohio State University (OSU) are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using cancer center resources to leverage group resources. OSU investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, trans planters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. The goal of this application is to provide the infrastructure to support OSU's participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (NLAPS). We will use the support to make scientific discoveries about tumor biology, find better treatments and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) Investigate new therapeutic agents, and their toxicities in Phase I to 1 clinical trials;2) Evaluate the efficacy nd toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively;3) Develop multi-modal approaches using surgical, immunological, and radio therapeutic measures in optimal combinations;4) Integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols;5) Improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) Understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) Improve the management of cancer related symptoms, and 8) enroll patients on trials.

Public Health Relevance

This grant supports OSUCCC's participation in the NCI's sponsored National Cooperative Clinical Trials Network in order to improve the prevention of cancer, better the treatment, and boost the cure rates of adults with cancer. OSUCCC has one of the largest volume academic cancer centers in the US and is fully engaged in NCTN research with each of the existing NCI supported cooperative groups.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180850-01
Application #
8605679
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-05-06
Project End
2019-02-28
Budget Start
2014-05-06
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$1,455,849
Indirect Cost
$509,468
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Castillo, Jorge J; Mulkey, Flora; Geyer, Susan et al. (2016) Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol 91:199-204
Chan, John K; Brady, Mark F; Penson, Richard T et al. (2016) Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med 374:738-48
Gu, Zhaohui; Churchman, Michelle; Roberts, Kathryn et al. (2016) Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. Nat Commun 7:13331
McMeekin, D Scott; Tritchler, David L; Cohn, David E et al. (2016) Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 34:3062-8
Bhatnagar, B; Blachly, J S; Kohlschmidt, J et al. (2016) Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3). Leukemia 30:1586-9
Palanichamy, Kamalakannan; Kanji, Suman; Gordon, Nicolaus et al. (2016) NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs and inhibits tumor forming ability. Clin Cancer Res :
Blum, W; Sanford, B L; Klisovic, R et al. (2016) Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503). Leukemia :
Buckner, Jan C; Shaw, Edward G; Pugh, Stephanie L et al. (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374:1344-55
Rocconi, Rodney P; Lankes, Heather A; Brady, William E et al. (2016) The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 140:264-9
Salamekh, Samer; Rong, Yi; Ayan, Ahmet S et al. (2016) Inter-Fraction Tumor Volume Response during Lung Stereotactic Body Radiation Therapy Correlated to Patient Variables. PLoS One 11:e0153245

Showing the most recent 10 out of 85 publications